Built using HealthPrize’s technology platform and based on peer-reviewed science and consumer marketing best practices, Max brings to pharma the three key ingredients for adherence success: the patient, the platform and the results.
September 17, 2019 – Norwalk, CT – HealthPrize Technologies, the leading provider of patient engagement, education and adherence technology for life science companies, today announced the release of Max, a single, integrated medication adherence experience targeting the most common chronic conditions. Built on HealthPrize’s proven-in-market platform, Max provides pharmaceutical companies with an easy-to-implement, end-to-end adherence solution encompassing patient enrollment and activation, ongoing engagement and education, and comprehensive program reporting.
Patients prescribed a brand’s medication are recruited through Max’s expanding partner ecosystem of pharmacies and population health companies. These Rx-verified patients engage daily with health content and actionable behavioral triggers specific to all of their prescribed medications. Refill activities are verified directly from Max’s partners to demonstrate adherence lift.
“Over the past eight years, we have established in more than 30 programs for pharmaceutical clients that HealthPrize’s approach of using peer-reviewed science and consumer marketing best practices can radically improve patient adherence,” said Tom Kottler, founder and chief growth officer of HealthPrize. “With Max, we’re expanding our offerings to bring to pharma the three key ingredients to scale that adherence success: the patient, the platform and the results.”
Earlier this year, HealthPrize released Drive, a product to develop and manage branded adherence programs configured to the unique requirements and challenges of a specific medication. Max, in contrast, is configured to the patient and provides education and medication management for all of their prescribed medications, ensuring adherence lift across the patient’s entire medicine cabinet.
Pharmaceutical clients can set patient recruitment targets at any level of scale; enrollment is limited to patients verified to be on their therapy who receive invitations from Max’s partner organizations. Because Max is not client-branded, medication-specific nor customizable, it requires limited effort from client brand teams, while providing the same high levels of engagement and adherence lift as branded adherence programs.
“Max overcomes several challenges that have typically been barriers to success for pharma-based adherence programs, including MLR review timing, complications and program scalability,” said John Ragland, chief product officer for HealthPrize. “Max is a closed system with both the user experience and patient enrollment fully managed by HealthPrize; pharma is purchasing data from patients verified to be prescribed their brands.”
Max, the result of nearly a decade of HealthPrize’s in-market experience, is a patient-centric adherence product with significant brand benefits. Pharmaceutical commercial teams managing medications for any of the following chronic conditions can sponsor Rx-verified patients to get the benefits of Max:
- Atrial fibrillation
- Heart failure
- Irritable Bowel Syndrome
Learn more at www.healthprize.com/max.